Congress Materials – Fall Clinical Dermatology Conference (FCDC 2025)
2025 Fall Clinical Dermatology Conference | Oct 23-26 | Las Vegas, NV
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Durability of Response to the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 1-Year ICONIC-TOTAL Findings
Edward Lain, Richard B. Warren, Melinda Gooderham, Robert Bissonnette, Yu-Huei Huang, Julien Ringuet, Matthias Hoffmann, Andreas Pinter, Joseph F. Merola, Jessica H. Rubens, Dorothy Fan, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Cynthia DeKlotz, Eingun James Song
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield, Ricardo Galimberti, Adelaide Hebert, Wenhui Wang, Jennifer Soung, Nina Magnolo, John Browning, Angela Moore, Mark Lebwohl, Dagmar Wilsmann-Theis, Georgios Kokolakis, Dariusch Mortazawi, Parbeer Grewal, Megan Miller, Joseph Cafone, Shu Li, Gigi Jiang, Fabio Nunes, Cynthia DeKlotz, Amy Paller
Icotrokinra Demonstrated Superior Responses Compared With Placebo and Deucravacitinib in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3 ICONIC-ADVANCE 1&2 Studies
Linda Stein Gold, April W. Armstrong, Robert Bissonnette, Nina Magnolo, Ronald B. Vender, Michael Sebastian, Maria Laura Galimberti, Athanasios Tsianakas, Marcelo Arnone, Paul Wallace, Margrit Simon, Josep Riera-Monroig, Bassey Effiom Edem, Jennifer Campbell, Ofelia Reyes-Servin, Lea Kephart, Yaung-Kaung Shen, Kellen Cresswell, Kim A. Papp
Impact and Insights of Psoriasis on Quality-of-Life and Shared Decision-Making among US Adolescents and Adults
Linda Stein Gold, Jennifer Soung, Nina Trenkler, Ashley Duenas, Laurie Conklin, Jensen Lewis, Timothy Fitzgerald, Gale Harding, Ya-Wen Yang, Guo Li,Mona Shahriari
Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
SPECTREM: Use of BSA x IGA to Evaluate Guselkumab Efficacy Through Week 48 in Participants With Low BSA, Moderate Plaque Psoriasis
Linda Stein Gold, Richard G. Langley, Theodore Alkousakis, H. Chih-ho Hong, Maxwell Sauder, Vlada Groysman, Jorge Garcia-Zuazaga, Katelyn Rowland, Jenny Jeyarajah, Alice B. Gottlieb, Joseph F. Merola, Bruce Strober
SPECTREM: Effect of Guselkumab on Patient-Reported Psoriasis Signs and Symptoms Through Week 48 in Participants with Low BSA, Moderate Psoriasis
April W. Armstrong, Brad P. Glick, David N. Adam, Jennifer Beecker, Virginie Kelly, James Krell, Theodore Alkousakis, Daphne Chan, Katelyn Rowland, Jenny Jeyarajah, Lorne Albrecht, Richard G. Langley
SPECTREM: High-Impact Site Skin Clearance and Itch Improvement Through Week 48 With Guselkumab in Participants With Low Body Surface Area, Moderate Psoriasis
Bruce Strober, Kim A. Papp, April W. Armstrong, Alice B. Gottlieb, James Krueger, Theodore Alkousakis, Katelyn Rowland, Daphne Chan, Jenny Jeyarajah, Laura Park-Wyllie, Robert Bissonnette
SPECTREM: Guselkumab Impact on Nail Psoriasis and Psoriatic Arthritis Through Week 48 in Participants With Low BSA, Moderate Psoriasis With High-Impact Site Involvement
Alice B. Gottlieb, Joseph F. Merola, Kim A. Papp, Marni Wiseman, Wei Jing Loo, Joe K. Tung, Theodore Alkousakis, Daphne Chan, Soumya D. Chakravarty, Jenny Jeyarajah, Richard G. Langley
SPECTREM: Skin Clearance Through Week 48 With Guselkumab in Participants With Low Body Surface Area, Moderate Plaque Psoriasis
Richard G. Langley, Linda Stein Gold, Joseph F. Merola, Kenneth B. Gordon, Theodore Alkousakis, Katelyn Rowland, Daphne Chan, Jenny Jeyarajah, Laura Park-Wyllie, Mark G. Lebwohl
Unmet Needs and Disease Burden: Perspectives from Adults with Psoriasis and Clinicians in the United States
Linda Stein Gold, Jennifer Soung, Nina Trenkler, Melina Taylor, Laurie Conklin, Jensen Lewis, Timothy Fitzgerald, Wesley Peters, Ya-Wen Yang, Guo Li, Mona Shahriari
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
